ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 17 No. 2 (2024), REVIEWS
Vol. 17 No. 2 (2024)
REVIEWS

Plasmablastic Lymphoma and Plasmablastic Myeloma: А Diagnostic Dilemma (Literature Review)

Published 01.04.2024
Mariya Vladimirovna Melnikova
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
A.M. Kovrigina
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
PDF_2024-17-2_129-140 (Russian)

Keywords

multiple myeloma
plasmablastic lymphoma
plasmablastic myeloma

How to Cite

Melnikova M.V., Kovrigina A.M. Plasmablastic Lymphoma and Plasmablastic Myeloma: А Diagnostic Dilemma (Literature Review). Clinical Oncohematology. 2024;(2):129–140. doi:10.21320/2500-2139-2024-17-2-129-140.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Plasmablastic lymphoma and plasmablastic myeloma are similar in morphology. Tumor substrate in both is characterized by large cells with blastic morphology, central or somewhat eccentric nuclei, large central nucleolus or some distinct nucleoli, and abundant eosinophilic cytoplasm. The common characteristic of both B-cell tumors is the expression of plasma cell differentiation markers (CD38, CD138, MUM-1/IRF-4, interferon regulatory factor 4, PRDM-1, PR domain zinc finger protein 1, and/or XBP-1, X-box-1 binding protein) with a frequent loss of CD20. These rare nosological entities with similar morphological and immunohistochemical features present a challenge for differential and reliable diagnosis. The present review deals with clinical signs, diagnostically significant immunohistochemical markers, and molecular genetic characteristics which are essential for differential diagnosis of plasmablastic lymphoma and plasmablastic myeloma.

PDF_2024-17-2_129-140 (Russian)

References

  1. Leoncini L, Montes-Moreno S, Miranda R, et al. Plasmablastic lymphoma. In: WHO Classification of Tumours. Haematolymphoid tumours (Internet). 5th ed., vol. 11. Lyon: IARC-Press; 2022. Available from: https://tumourclassification.iarc.who.int (accessed 1.11.23).
  2. Leopold GD, Dotlic S, Mahdi AJ, et al. Differential diagnosis of aggressive neoplasms with plasmablastic and late post-follicular differentiation. Diagn Histopathol. 2020;26(9):421–39. doi: 10.1016/j.mpdhp.2020.07.001.
  3. Zhou J, Nassiri M. Lymphoproliferative Neoplasms With Plasmablastic Morphology. Arch Pathol Lab Med. 2022;146(4):407–14. doi: 10.5858/arpa.2021-0117-RA.
  4. Wu J, Chu E, Chase CC, et al. Anaplastic Multiple Myeloma: Case Series and Literature Review. Asploro J Biomed Clin Case Rep. 2022;5(1):1–11. doi: 10.36502/2022/asjbccr.6255.
  5. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–107. doi: 10.1002/ajh.26590.
  6. Gahrton G, Durie B, Samson D. (eds.) Multiple Myeloma and Related Disorders. CRC Press; 2004. doi: 10.1201/b13347.
  7. Kumar S, Medeiros LJ, Gujral S, et al. Plasma cell myeloma/multiple myeloma. In: WHO Classification of Tumours. Haematolymphoid tumours (Internet). 5th ed., vol. 11. Lyon: IARC-Press; 2022. Available from: https://tumourclassification.iarc.who.int (accessed 1.11.23).
  8. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. и др. Клинические рекомендации «Множественная миелома» МЗ РФ 2020 (электронный документ). Доступно по: https://base.garant.ru/405950863/53f89421bbdaf741eb2d1ecc4ddb4c33/ Ссылка активна на 1.11.2023. [Mendeleeva LP, Votyakova OM, Rekhtina IG, et al. Clinical guidelines “Multiple Myeloma”, Ministry of Health of the Russian Federation (Internet). Available from: https://base.garant.ru/405950863/53f89421bbdaf741eb2d1ecc4ddb4c33/ Accessed 1.11.2023. (In Russ)]
  9. Kumar SK, Callander NS, Adekola K, et al. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8–19. doi: 10.6004/jnccn.2022.0002.
  10. Mori H, Fukatsu M, Ohkawara H, et al. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. Int J Hematol. 2021;114(6):639–52. doi: 10.1007/s12185-021-03211-w.
  11. Chen B-J, Chuang S-S. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. Adv Anat Pathol. 2020;27(2):61–74. doi: 10.1097/PAP.0000000000000253.
  12. Ahn JS, Okal R, Vos JA, et al. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol. 2017;70(9):775–80. doi: 10.1136/jclinpath-2016-204294.
  13. Лушова А.А., Жеремян Э.А., Астахова Е.А. и др. Субпопуляции В-лимфоцитов: функции и молекулярные маркеры. Иммунология. 2019;40(6):63–76. doi: 10.24411/0206-4952-2019-16009. [Lushova AA, Zheremyan EA, Astahova EA, et al. B-lymphocyte subsets: functions and molecular markers. Immunologiya. 2019;40(6):63–76. doi: 10.24411/0206-4952-2019-16009. (In Russ)]
  14. Naresh KN, Ferry AJ, Qu MQ, et al. Introduction to B-cell lymphoproliferative disorders and neoplasms. In: WHO Classification of Tumours. Haematolymphoid tumours (Internet). 5th ed., vol. 11. Lyon: IARC-Press; 2022. Available from: https://tumourclassification.iarc.who.int (accessed 1.11.23).
  15. Heider M, Nickel K, Hogner M, Bassermann F. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncol Res Treat. 2021;44(12):672–81. doi: 10.1159/000520312.
  16. Bailly J, Jenkins N, Chetty D, et al. Plasmablastic lymphoma: An update. Int J Lab Hematol. 2022;44(Suppl 1):54–63. doi: 10.1111/ijlh.13863.
  17. Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682–93. doi: 10.3324/haematol.2020.271957.
  18. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413–20.
  19. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32. doi: 10.1182/blood-2011-01-293050.
  20. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol. 2001;19(4):129–50. doi: 10.1002/hon.660.
  21. Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28(4):843–8. doi: 10.1093/annonc/mdw684.
  22. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323–30. doi: 10.1182/blood-2014-10-567479.
  23. Hess BT, Giri A, Park Y, et al. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023;98(2):300–8. doi: 10.1002/ajh.26784.
  24. Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023;21(11):1118–31. doi: 10.6004/jnccn.2023.0057.
  25. Фирсова М.В., Соловьев М.В., Ковригина А.М., Менделеева Л.П. Плазмобластная лимфома с первичным поражением костного мозга у пациента с ВИЧ-отрицательным статусом: обзор литературы и собственное клиническое наблюдение. Клиническая онкогематология. 2022;15(4):356–64. doi: 10.21320/2500-2139-2022-15-4-356-364. [Firsova MV, Solov’ev MV, Kovrigina AM, Mendeleeva LP. Plasmablastic Lymphoma with Primary Impairment of Bone Marrow in a HIV-Negative Patient: A Literature Review and a Case Report. Clinical oncohematology. 2022;15(4):356–64. doi: 10.21320/2500-2139-2022-15-4-356-364. (In Russ)]
  26. Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020;52(1):53–67. doi: 10.1016/j.pathol.2019.08.013.
  27. Chen BJ, Yuan CT, Yang CF, et al. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. Virchows Arch. 2022;481(2):283–93. doi: 10.1007/s00428-022-03342-3.
  28. Frontzek F, Staiger AM, Zapukhlyak M, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12(1):5183. doi: 10.1038/s41467-021-25405-w.
  29. Kuppers R. The Genomic Landscape of HIV-Associated Plasmablastic Lymphoma. Blood Cancer Discov. 2020;1(1):23–5. doi: 10.1158/2643-3249.BCD-20-0075.
  30. Witte HM, Kunstner A, Hertel N, et al. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Adv. 2022;6(2):637–51. doi: 10.1182/bloodadvances.2021005486.
  31. Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682–93. doi: 10.3324/haematol.2020.271957.
  32. Fujino M. The histopathology of myeloma in the bone marrow. J Clin Exp Hematop. 2018;58(2):61–7. doi: 10.3960/jslrt.18014.
  33. Мамаева Е.А., Соловьева М.В., Менделеева Л.П. Множественная миелома, осложненная костными плазмоцитомами: патогенез, клиническая картина, лечебные подходы (обзор литературы). Клиническая онкогематология. 2023;16(3):303–10. doi: 10.21320/2500-2139-2023-16-3-303-310. [Mamaeva EA, Soloveva MV, Mendeleeva LP. Multiple Myeloma Complicated by Bone Plasmacytomas: Pathogenesis, Clinical Features, Treatment Approaches (A Literature Review). Clinical oncohematology. 2023;16(3):303–10. (In Russ)]
  34. Фирсова М.В., Рисинская Н.В., Соловьев М.В. и др. Множественная миелома с экстрамедуллярной плазмоцитомой: аспекты патогенеза и клиническое наблюдение. Онкогематология. 2022;17(4):67–80. doi: 10.17650/1818-8346-2022-17-4-67-80. [Firsova MV, Risinskaya NV, Solovev MV, et al. Multiple myeloma with extramedullary plasmacytoma: pathogenesis and clinical case. Oncohematology. 2022;17(4):67–80. doi: 10.17650/1818-8346-2022-17-4-67-80. (In Russ)]
  35. Сергеева А.М., Абрамова Т.В., Сурин В.Л. и др. Сравнение молекулярно-генетической структуры опухолевых клеток до лечения и после констатации рецидива множественной миеломы (краткий обзор и описание клинического случая). Гематология и трансфузиология. 2019;64(3):362–74. doi: 10.35754/0234-5730-2019-64-3-362-374. [Sergeeva AM, Abramova TV, Surin VL, et al. Molecular genetic structure of multiple myeloma tumour cells prior to treatment and at the time of relapse: short review and case report. Russian journal of hematology and transfusiology. 2019;64(3):362–74. doi: 10.35754/0234-5730-2019-64-3-362-374. (In Russ)]
  36. Ichikawa S, Fukuhara N, Hashimoto K, et al. Anaplastic multiple myeloma with MYC rearrangement. Leuk Res Rep. 2021;17:100288. doi: 10.1016/j.lrr.2021.100288.
  37. Pileri S, Poggi S, Baglioni P, et al. Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol Suppl. 1989;51:52–9. doi: 10.1111/j.1600-0609.1989.tb01493.x.
  38. Petruch UR, Horny H-P, Kaiserling E. Frequent expression of haemopoietic and non-haemopoietic antigens by neoplastic plasma cells: an immunohistochemical study using formalin-fixed, paraffin-embedded tissue. Histopathology. 1992;20(1):35–40. doi: 10.1111/j.1365-2559.1992.tb00913.x.
  39. Adams H, Schmid P, Dirnhofer S, Tzankov A. Cytokeratin expression in hematological neoplasms: A tissue microarray study on 866 lymphoma and leukemia cases. Pathol Res Pract. 2008;204(8):569–73. doi: 10.1016/j.prp.2008.02.008.
  40. Gulati R, Jamal M, Inamdar K, et al. Cytokeratin Expression In Plasmacytomas: A Comprehensive Analysis Using Modern Cytokeratin Cocktails. Am J Clin Pathol. 2015;144(Suppl_2):A148. doi: 10.1093/ajcp/144.suppl2.148.
  41. Padhi S, Varghese RG, Ramdas A. Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review. Indian J Med Paediatr Oncol. 2013;34(4):283–91. doi: 10.4103/0971-5851.125246.
  42. Natkunam Y, Tedoldi S, Paterson JC, et al. Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia. Am J Clin Pathol. 2009;132(3):361–71. doi: 10.1309/AJCPEAGDKLWDMB1O.
  43. Chang H, Qi Q, Xu W, Patterson B. c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. 2007;21(7):1572–4. doi: 10.1038/sj.leu.2404669.
  44. Tanaka T, Ichimura K, Sato Y, et al. Frequent downregulation or loss of CD79a expression in plasma cell myelomas: Potential clue for diagnosis. Pathol Int. 2009;59(11):804–8. doi: 10.1111/j.1440-1827.2009.02448.x.
  45. Boucher K, Parquet N, Widen R, et al. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012;18(22):6155–68. doi: 10.1158/1078-0432.CCR-12-0531.
  46. Marks E, Shi Y, Wang Y. CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma. Histopathology. 2017;71(1):81–8. doi: 10.1111/his.13196.
  47. Krenacs D, Borbenyi Z, Bedekovics J, et al. Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. Virchows Arch. 2015;467(3):345–55. doi: 10.1007/s00428-015-1796-6.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Clinical Oncohematology